Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now

Publisher:
Springer Science + Business Media B.V.
Publication Type:
Journal Article
Citation:
International Journal of Clinical Pharmacy, 2012, 34 pp. 88 - 97
Issue Date:
2012-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2011006088OK.pdf249.21 kB
Adobe PDF
Objective Evidence from pivotal clinical trials conducted more than a decade ago supports the use of antithrombotic therapy, particularly warfarin, for stroke prevention in atrial fibrillation (AF). Despite the wide dissemination of this evidence since that time, there is anecdotal evidence that utilisation of therapy remains suboptimal, especially in the target elderly population, which is reflected in the development of practice tools such as the TAG Clinical Indicator ('Antithrombotics in AF' Indicator 1.6, 2007). Therefore, the objective of this study was to determine the current utilisation of antithrombotic therapy for elderly patients with AF in the local setting, and to compare this utilisation with the results of a prior audit (AUDIT 1), as well as against the recommendations of the TAG Clinical Indicator(TAG IND).
Please use this identifier to cite or link to this item: